Skip to content
OpenCapital
Get started

Unicycive Therapeutics, Inc. UNCY Q4 2025 Annual earnings

Reported March 30, 2026

EPS-$0.32Beat by $0.19
Revenue estimate$517.0K
EPS estimate-$0.51

Next report

Aug 13, 2026 (In 2 weeks)
Revenue estimate$22.2M
EPS estimate-$0.47

Versus estimates

Diluted EPS

Q1 2026-$0.54Miss by $0.08
Q4 2025-$0.32Beat by $0.19
Q3 2025-$0.39Beat by $0.20Q2 2025-$0.52Beat by $0.18Q1 2025-$0.26Miss by $0.13Q4 2024-$0.16Miss by $0.03

Ask the moment Unicycive Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Unicycive Therapeutics, Inc. report Q4 2025 earnings?
Unicycive Therapeutics, Inc. (UNCY) reported Q4 2025 earnings on March 30, 2026.
What were Unicycive Therapeutics, Inc.'s Q4 2025 revenue and EPS?
Unicycive Therapeutics, Inc. reported eps of $-0.32 for Q4 2025.
Did Unicycive Therapeutics, Inc. beat estimates in Q4 2025?
EPS beat the consensus estimate of $-0.51 by $0.19.
How did Unicycive Therapeutics, Inc.'s Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps declined 100.0% from $-0.16.
Where can I find Unicycive Therapeutics, Inc.'s Q4 2025 SEC filings?
You can read the 8-K earnings release (0001213900-26-035961) and the 10-K periodic report (0001213900-26-035903) directly on SEC EDGAR. The filing index links above go to sec.gov.